Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Somatic nervous system

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    13 result(s) found for: Somatic nervous system. Displaying page 1 of 1.
    EudraCT Number: 2017-002949-30 Sponsor Protocol Number: ATA129-EBV-302 Start Date*: 2020-07-17
    Sponsor Name:Atara Biotherapeutics, Inc.
    Full Title: Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative D...
    Medical condition: Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068349 Epstein-Barr virus associated lymphoproliferative disorder PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075146 Post transplant Epstein-Barr virus associated lymphoproliferative disorder LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000177-25 Sponsor Protocol Number: ATA129-EBV-205 Start Date*: 2021-01-04
    Sponsor Name:Atara Biotherapeutics, Inc.
    Full Title: An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstein-Barr Virus-associated Diseases
    Medical condition: • EBV+ primary imunodeficiency lymphoproliferative disease (LPD) • EBV+ LPD in the setting of acquired (non-congenital) immunodeficiency • EBV+ post-transplant LPD involving the central nervous ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068349 Epstein-Barr virus associated lymphoproliferative disorder PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003200-14 Sponsor Protocol Number: JR-141-GS31 Start Date*: 2022-05-16
    Sponsor Name:JCR Pharmaceuticals Co., Ltd.
    Full Title: A Phase III study of JR-141 in Mucopolysaccharidosis type II (Hunter Syndrome) patients.
    Medical condition: Mucopolysaccharidosis type II
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10056889 Mucopolysaccharidosis II PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002358-22 Sponsor Protocol Number: C1201 Start Date*: 2012-08-06
    Sponsor Name:Biologische Heilmittel Heel GmbH
    Full Title: NEUPRO DB, efficacy profile of Neurexan in an experimental acute stress setting – an explorative double blind study in healthy probands
    Medical condition: Neurexan to be effective in fostering mental balance by reducing tension and nervousness during acute stress setting in healthy probands
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004848 10042219 Stress test LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002359-40 Sponsor Protocol Number: C1202 Start Date*: 2012-07-18
    Sponsor Name:Biologische Heilmittel Heel GmbH
    Full Title: NEUPRO OL, Efficacy profile of Neurexan® in an experimental acute stress setting – an explorative open-label study in healthy probands
    Medical condition: Neurexan to be effective in fostering mental balance by reducing tension and nervousness during acute stress setting in healthy probands
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004848 10042219 Stress test LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001195-21 Sponsor Protocol Number: SFK3 Start Date*: 2015-10-19
    Sponsor Name:Sørlandet Hospital
    Full Title: NoTOPain Novel Treatment Option for neuropathic Pain A randomized, cross-over, placebo-controlled, double-blind, single-center, phase II study of cetuximab in patients with treatment-refracto...
    Medical condition: Neuropathic pain conditions, i.e. radiculopathy or Complex regional pain syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003570-31 Sponsor Protocol Number: ONITT Start Date*: 2021-07-19
    Sponsor Name:St. Jude Children's Research Hospital
    Full Title: A Randomized Phase I/II Study of Onivyde in Combination with Talazoparib or Temozolomide in Children and Young Adults with Recurrent Solid Malignancies and Ewing Sarcoma
    Medical condition: EWING SARCOMA
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015562 Ewing's sarcoma metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015560 Ewing's sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015564 Ewing's sarcoma recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065143 Malignant solid tumour LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2018-003546-16 Sponsor Protocol Number: Debio1143-106 Start Date*: 2019-03-06
    Sponsor Name:Debiopharm International SA
    Full Title: SMARTPLUS-106: Debio 1143 a SMAC Mimetic In Combination With Nivolumab In Patients Failing Prior PD-1/PD-L1 Treatment: A Basket Trial A dose-optimization, exploratory phase Ib/II study to assess...
    Medical condition: Solid Tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-002382-19 Sponsor Protocol Number: PDC-LUNG-101 Start Date*: 2019-06-13
    Sponsor Name:PDC*line Pharma SAS
    Full Title: An open-label, dose-escalation, phase I/II study to assess the safety, the tolerability, the immunogenicity and the preliminary clinical activity of the therapeutic cancer vaccine, PDC*lung01, asso...
    Medical condition: Non-small-cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002468-18 Sponsor Protocol Number: EZH-102 Start Date*: 2016-02-19
    Sponsor Name:Epizyme, Inc.
    Full Title: A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects with Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
    Medical condition: Atypical teratoid rhabdoid tumor (ATRT), Malignant rhabdoid tumor (MRT), Rhabdoid tumor of kidney (RTK), selected tumors with rhabdoid features. Epithelioid sarcoma, Epithelioid malignant peripher...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064886 Renal medullary carcinoma LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065870 Atypical teratoid/rhabdoid tumor of CNS LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073134 Extraskeletal myxoid chondrosarcoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073335 Rhabdoid tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074121 Rhabdoid tumor of the kidney LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042863 Synovial sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015100 Epithelioid sarcomas HLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) DE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004750-21 Sponsor Protocol Number: TAK-935-2008 Start Date*: 2019-06-10
    Sponsor Name:Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda
    Full Title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 as an Adjunctive Therapy in Adult Subjects With Chronic Complex Regional...
    Medical condition: Complex Regional Pain Syndrome (CRPS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10064334 Complex regional pain syndrome Type I LLT
    21.1 100000004852 10064335 Complex regional pain syndrome Type II LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-001205-23 Sponsor Protocol Number: OVERLORD-MS Start Date*: 2020-07-10
    Sponsor Name:Helse Bergen HF, Haukeland University Hospital
    Full Title: Ocrelizumab VErsus Rituximab off-Label at the Onset of Relapsing MS Disease (OVERLORD-MS)
    Medical condition: Remitting Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-000072-42 Sponsor Protocol Number: RG_11-087 Start Date*: 2013-02-06
    Sponsor Name:The University of Birmingham
    Full Title: A randomised phase IIb trial of bevacizumab added to temozolomide ± irinotecan for children with refractory/relapsed neuroblastoma – BEACON-Neuroblastoma Trial
    Medical condition: Neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10029261 Neuroblastoma NOS LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) DK (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) IT (Completed) AT (Completed) DE (Prematurely Ended) BE (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 16 15:01:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA